Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 3
2016 7
2017 13
2018 12
2019 14
2020 13
2021 21
2022 30
2023 27
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Results by year

Filters applied: . Clear all
Page 1
Impact of the presence and number of chromosomal abnormalities on the clinical outcome in Waldenström Macroglobulinemia: a monocentric experience.
Danesin N, Bonaldi L, Martines A, Nalio S, Bertorelle R, Compagno S, Marcato R, Manni S, Scarmozzino F, Pizzi M, Tos APD, Cellini A, Scapinello G, Visentin A, Trentin L, Piazza F. Danesin N, et al. Among authors: visentin a. Ann Hematol. 2024 Apr 30. doi: 10.1007/s00277-024-05770-4. Online ahead of print. Ann Hematol. 2024. PMID: 38687347
When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenario.
Danesin N, Scapinello G, Del Prete D, Naso E, Berno T, Visentin A, Bonaldi L, Martines A, Bertorelle R, Vianello F, Gurrieri C, Zambello R, Castellani C, Fedrigo M, Rizzo S, Angelini A, Trentin L, Piazza F. Danesin N, et al. Among authors: visentin a. Cancer Rep (Hoboken). 2024 Apr;7(4):e2062. doi: 10.1002/cnr2.2062. Cancer Rep (Hoboken). 2024. PMID: 38662353 Free PMC article.
Chronic Lymphocytic Leukemia (CLL) with Borderline Immunoglobulin Heavy Chain Mutational Status, a Rare Subgroup of CLL with Variable Disease Course.
Angotzi F, Cellini A, Ruocco V, Cavarretta CA, Zatta I, Serafin A, Pravato S, Pagnin E, Bonaldi L, Frezzato F, Facco M, Piazza F, Trentin L, Visentin A. Angotzi F, et al. Among authors: visentin a. Cancers (Basel). 2024 Mar 8;16(6):1095. doi: 10.3390/cancers16061095. Cancers (Basel). 2024. PMID: 38539430 Free PMC article.
p66Shc deficiency in CLL cells enhances PD-L1 expression and suppresses immune synapse formation.
Lopresti L, Capitani N, Tatangelo V, Tangredi C, Boncompagni G, Frezzato F, Visentin A, Marotta G, Ciofini S, Gozzetti A, Bocchia M, Trentin L, Baldari CT, Patrussi L. Lopresti L, et al. Among authors: visentin a. Front Cell Dev Biol. 2024 Jan 23;12:1297116. doi: 10.3389/fcell.2024.1297116. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38389706 Free PMC article.
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.
Boncompagni G, Tatangelo V, Lopresti L, Ulivieri C, Capitani N, Tangredi C, Finetti F, Marotta G, Frezzato F, Visentin A, Ciofini S, Gozzetti A, Bocchia M, Calzada-Fraile D, Martin Cofreces NB, Trentin L, Patrussi L, Baldari CT. Boncompagni G, et al. Among authors: visentin a. Cell Death Dis. 2024 Feb 15;15(2):144. doi: 10.1038/s41419-024-06528-6. Cell Death Dis. 2024. PMID: 38360867 Free PMC article.
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
Autore F, Visentin A, Deodato M, Vitale C, Galli E, Fresa A, Fazzi R, Sanna A, Olivieri J, Scortechini I, Del Principe MI, Sportoletti P, Schiattone L, Maschio N, Facchinelli D, Marchesi F, Coscia M, Tedeschi A, Trentin L, Innocenti I, Candoni A, Busca A, Pagano L, Laurenti L. Autore F, et al. Among authors: visentin a. Am J Hematol. 2024 May;99(5):982-984. doi: 10.1002/ajh.27247. Epub 2024 Feb 11. Am J Hematol. 2024. PMID: 38343033 No abstract available.
134 results